IL108368A0 - Spirocycloalkyl-substituted azetidinones useful as hypocholestrerolemic agents - Google Patents

Spirocycloalkyl-substituted azetidinones useful as hypocholestrerolemic agents

Info

Publication number
IL108368A0
IL108368A0 IL10836894A IL10836894A IL108368A0 IL 108368 A0 IL108368 A0 IL 108368A0 IL 10836894 A IL10836894 A IL 10836894A IL 10836894 A IL10836894 A IL 10836894A IL 108368 A0 IL108368 A0 IL 108368A0
Authority
IL
Israel
Prior art keywords
optionally
alkenylene
sum
substituted
image
Prior art date
Application number
IL10836894A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL108368A0 publication Critical patent/IL108368A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL10836894A 1993-01-21 1994-01-19 Spirocycloalkyl-substituted azetidinones useful as hypocholestrerolemic agents IL108368A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US643993A 1993-01-21 1993-01-21

Publications (1)

Publication Number Publication Date
IL108368A0 true IL108368A0 (en) 1994-04-12

Family

ID=21720894

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10836894A IL108368A0 (en) 1993-01-21 1994-01-19 Spirocycloalkyl-substituted azetidinones useful as hypocholestrerolemic agents

Country Status (26)

Country Link
US (1) US5698548A (fr)
EP (1) EP0681569B1 (fr)
JP (1) JP2719445B2 (fr)
KR (1) KR960700227A (fr)
CN (1) CN1118163A (fr)
AT (1) ATE199899T1 (fr)
AU (1) AU683048B2 (fr)
CA (1) CA2154257C (fr)
CZ (1) CZ180195A3 (fr)
DE (1) DE69426924T2 (fr)
DK (1) DK0681569T3 (fr)
EE (1) EE9400394A (fr)
ES (1) ES2155849T3 (fr)
FI (1) FI953497A0 (fr)
GR (1) GR3035963T3 (fr)
HU (1) HUT72592A (fr)
IL (1) IL108368A0 (fr)
LT (1) LT3595B (fr)
NO (1) NO952884L (fr)
NZ (1) NZ261714A (fr)
PL (1) PL309978A1 (fr)
PT (1) PT681569E (fr)
SI (1) SI9400022A (fr)
SK (1) SK91195A3 (fr)
WO (1) WO1994017038A1 (fr)
ZA (1) ZA94386B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU94046294A (ru) * 1992-06-26 1996-10-10 Пфайзер Инк. (US) Стероидные гликозиды для лечения гиперхолестеринэмии
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
HU226822B1 (en) * 1995-10-31 2009-11-30 Schering Corp Hypocholesterolemic sugar-substituted 2-azetidinones, and pharmaceutical compns. contg. them
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
CZ302193B6 (cs) * 2000-12-20 2010-12-08 Schering Corporation 2-azetidinonové deriváty, substituované zbytkem cukru
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
EP1911462A3 (fr) 2001-01-26 2011-11-30 Schering Corporation Combinaisons comprenant un inhibiteur d'absorption de stérol
WO2002058734A2 (fr) * 2001-01-26 2002-08-01 Schering Corporation Combinaisons d'inhibiteur(s) d'absorption des sterols et de modificateur(s) sanguin(s) pour le traitement des troubles vasculaires
PL205343B1 (pl) * 2001-01-26 2010-04-30 Schering Corp Zastosowanie inhibitora wchłaniania sterolu
WO2002079174A2 (fr) 2001-03-28 2002-10-10 Schering Corporation Synthese enantioselective de composes intermediaires d'azetidinone
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
EP1859796A3 (fr) * 2001-09-21 2008-07-02 Schering Corporation Treatment de xanthoma avec des dérivés d'azétidines en tant qu'inhibiteurs d'absorption des stérols
EP1429756B1 (fr) * 2001-09-21 2006-11-22 Schering Corporation Methodes et combinaisons therapeutiques utiles pour le traitement du xanthome effectue avec des inhibiteurs d'absorption du sterol
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004010948A2 (fr) * 2002-07-30 2004-02-05 Karykion Inc. Compositions d'ezetimibe, et procedes pour le traitement de tumeurs benignes et malignes associees au cholesterol
WO2004081002A1 (fr) 2003-03-07 2004-09-23 Schering Corporation Composes d'azetidinone substitues, leurs formulations et utilisations en vue du traitement de l'hypercholesterolemie
US7208486B2 (en) 2003-03-07 2007-04-24 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EA200701782A3 (ru) 2003-04-24 2008-04-28 Инсайт Корпорейшн Производные азаспироалканов в качестве ингибиторов металлопротеаз
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1918000A2 (fr) 2003-11-05 2008-05-07 Schering Corporation Combinaisons d'agents de modulation lipide et azétidinones substitués et traitements pour conditions vasculaires
WO2005046797A2 (fr) * 2003-11-05 2005-05-26 Schering Corporation Combinaisons de modulateurs lipidiques et d'azetidinones substituees et traitements d'affections vasculaires
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
WO2005069900A2 (fr) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) et procédés pour identifier des ligands de ceux-ci
US7291728B2 (en) 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
EP1676836A1 (fr) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Hydroxylation, fonctionnalisation et protection regioselective de spirolactames
EP1598336A1 (fr) * 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Hydroxylation, fonctionnalisation et protection regioselective de spirolactames
JP2007536329A (ja) * 2004-05-10 2007-12-13 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ スピロラクタム類の位置選択的官能化および保護
US20080045726A1 (en) * 2004-05-10 2008-02-21 Laboratorios Del Dr. Esteve, S.A. Spirolactams and Their Synthesis
JP2008514718A (ja) * 2004-09-29 2008-05-08 シェーリング コーポレイション 置換アゼチドノンおよびｃｂ１アンタゴニストの組み合わせ
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
WO2006107936A1 (fr) * 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile Utilisation d'ezetimibe pour prevenir et traiter des calculs biliaires de cholesterol
WO2007001975A1 (fr) * 2005-06-20 2007-01-04 Schering Corporation Dérivés de la pipéridine utiles comme antagonistes du récepteur h3 de l'histamine
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
CA2637565A1 (fr) 2006-01-18 2007-07-26 Schering Corporation Modulateurs de recepteurs de cannibinoides
EP1986489A2 (fr) * 2006-02-24 2008-11-05 Schering Corporation Orthologues de npc1l1
TW200811098A (en) 2006-04-27 2008-03-01 Astrazeneca Ab Chemical compounds
WO2008030382A1 (fr) * 2006-09-05 2008-03-13 Schering Corporation Compositions pharmaceutiques pour un traitement des lipides et dans le traitement de l'athérosclérose et de la stéatose hépatique
WO2008033447A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidine et d'azétidone convenant dans le traitement de la douleur et des troubles du métabolisme des lipides
WO2008033465A1 (fr) * 2006-09-15 2008-03-20 Schering Corporation Dérivés d'azétidinone et procédés d'utilisation de ceux-ci
CN101528746A (zh) * 2006-09-15 2009-09-09 先灵公司 治疗脂质代谢障碍、疼痛、糖尿病和其它障碍的螺环氮杂环丁酮衍生物
EP2061462A2 (fr) * 2006-09-15 2009-05-27 Schering Corporation Procédé de traitement de la douleur, du diabète et des troubles du métabolisme lipidique
EP2061792A2 (fr) * 2006-09-15 2009-05-27 Schering Corporation Dérivés d'azétidinone et procédés d'utilisation de ceux-ci
MX2009002922A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
JP2010503675A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
WO2008130616A2 (fr) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines comme modulateurs des récepteurs cb1
EP2170847A2 (fr) * 2007-06-28 2010-04-07 Intervet International BV Pipérazines à substitution servant d'antagonistes des récepteurs cb1
KR20100051625A (ko) 2007-06-28 2010-05-17 인터벳 인터내셔널 비.브이. Ｃｂ1 길항제로서의 치환된 피페라진
US9212175B2 (en) 2009-03-06 2015-12-15 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
EP2547679B1 (fr) 2010-03-19 2015-11-04 Pfizer Inc Derivés de 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane et leur utilisation en tant qu'antagonistes ou agonistes du récepteur de la ghréline
DK2844233T3 (da) 2012-05-01 2020-07-13 Althera Life Sciences Llc Oral tabletformulering bestående af en fastsat kombination af rosuvastatin og ezetimib til behandling af hyperlipidæmi og kardiovaskulære sygdomme
CN104496838B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
WO2020104930A1 (fr) 2018-11-20 2020-05-28 Piramal Enterprises Limited Synthèse asymétrique améliorée de composés azaspiro
WO2020191163A1 (fr) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Traitement de niveaux de lipides accrus avec des inhibiteurs de protéine d'activation de clivage de protéine de liaison d'élément régulateur de stérol (scap)
EP3942048A1 (fr) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Traitement de niveaux de lipides accrus avec des inhibiteurs du facteur de transcription 1 de liaison à un élément régulateur de stérol (srebf1)
AU2022421224A1 (en) * 2021-12-22 2024-06-20 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2048080C3 (de) * 1970-09-30 1979-11-29 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
IL89835A0 (en) 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
CZ14294A3 (en) 1991-07-23 1994-07-13 Schering Corp Substituted beta-lactam compounds usable as hypocholesterol pharmaceutical preparations and process for preparing thereof

Also Published As

Publication number Publication date
DK0681569T3 (da) 2001-04-23
NO952884L (no) 1995-09-20
CZ180195A3 (en) 1996-01-17
DE69426924D1 (de) 2001-04-26
NO952884D0 (no) 1995-07-20
ES2155849T3 (es) 2001-06-01
FI953497A (fi) 1995-07-20
WO1994017038A1 (fr) 1994-08-04
SI9400022A (en) 1995-02-28
AU6087294A (en) 1994-08-15
EE9400394A (et) 1996-06-17
CA2154257C (fr) 1999-05-25
HUT72592A (en) 1996-05-28
JP2719445B2 (ja) 1998-02-25
CA2154257A1 (fr) 1994-08-04
PT681569E (pt) 2001-06-29
US5698548A (en) 1997-12-16
KR960700227A (ko) 1996-01-19
NZ261714A (en) 1997-02-24
EP0681569A1 (fr) 1995-11-15
ATE199899T1 (de) 2001-04-15
CN1118163A (zh) 1996-03-06
EP0681569B1 (fr) 2001-03-21
DE69426924T2 (de) 2001-08-16
GR3035963T3 (en) 2001-08-31
LTIP1764A (en) 1995-02-27
FI953497A0 (fi) 1995-07-20
SK91195A3 (en) 1995-12-06
LT3595B (en) 1995-12-27
PL309978A1 (en) 1995-11-13
JPH08501110A (ja) 1996-02-06
ZA94386B (en) 1994-07-19
AU683048B2 (en) 1997-10-30
HU9502194D0 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
ZA94386B (en) Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
MY130157A (en) Method of use for inhibiting bone loss and lowering serum cholesterol
AU616386B2 (en) Pharmaceutical compositions
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
CZ208895A3 (en) Novel imidazopyridine compounds, process for preparing such compounds and their salts, the use of said compounds and salts in the preparation of medicaments and a medicament containing thereof
CA2240717A1 (fr) Methode de diagnostic et de traitement des troubles de la respiration pendant le sommeil et dispositif de mise en oeuvre de cette methode
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
HUT49614A (en) Process for producing cefalosporin derivatives and pharmaceutical compositions comprising these compounds
TW339327B (en) Substituted benzoylguanidines, a process for their manufacture, their use as a medicament or diagnostic, as well as medicaments containing them
RU2091378C1 (en) 7-acyl-3-substituted carbamoylhydroxycephems, methods of their synthesis, substituted carbamoylhydroxy-3-cephems, methods of their synthesis and antibacterial composition
IL108288A0 (en) Pyrrolidine derivatives, their preparation and medicaments containing them
TW261605B (fr)
BR9910185A (pt) Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana
IL112110A0 (en) Octahydro-1h-isoindoles and pharmaceutical compositions containing them
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
AU2788995A (en) Fungicidal mixtures
EP0363223A3 (fr) Dérivés de 3-aryloxyméthylcéphalosporine, leur préparation et applications pharmaceutiques
SE9401596D0 (sv) New compounds
MX9601852A (es) Formulaciones de estramustina con propiedades farmaceuticas mejoradas.
UA66867C2 (uk) 19-норстероїди, галогеновані в положенні 17, спосіб їх отримання, фармацевтична композиція та лікарський засіб, проміжні продукти
HU9401458D0 (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments
DK549085A (da) 3-aminopropoxyphenylderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater, som indeholder disse derivater
ES2136018A1 (es) Compuestos inhibidores selectivos de la ciclooxigenasa-i y su utilizacion como analgesicos, antiinflamatorios y antiartriticos.